Transaction · 0001918845-26-000029

Doyle Mittie

Doyle Mittie, CMO, reported a transaction classified as exercise at Avalo Therapeutics, Inc. involving 1000.000000 shares for an estimated $12650.00. Reported holdings after the transaction were 52776.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MCMO
AVTXAvalo Therapeutics, Inc.
Filing timeAug 19
Trade dateAug 17, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$20.75
Pre-filing
1mo ago -6.7%1w ago -4.7%1d ago -5.6%
Returns since
7d -1.0%30d -8.7%90d -8.7%180d -8.7%1y -8.7%

AVTX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
AVTX since 2026-08-19Filed 15 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001918845-26-000029
Common Stock
Transaction date
Aug 17, 2026
Filed Aug 19, 2026, 08:10 PM · 2d delay
Shares
1.00k sh
$1.26k per share
Estimated value
$1.26M
Computed from shares × price
Holdings after
52.7k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

  2. F2

    The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's contin…

Original filing · 0001918845-26-000029
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

AVTX